Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferons and hematology].

L Lacotte-Thierry1, F Guilhot

  • 1Service d'oncologie hématologique et de thérapie cellulaire, CHU de Poitiers, rue de la Milètrie, 86021 Poitiers, France. l.lacotte@chu-poitiers.fr

La Revue De Medecine Interne
|December 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Human cells for therapeutics purpose: State of the art].

Bulletin de l'Academie nationale de medecine·2020
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid.

Journal of controlled release : official journal of the Controlled Release Society·2017
Same author

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Bone marrow transplantation·2017
Same author

Cytogenetic Remissions in Chronic Myelogenous Leukemia Using Interferon Alpha-2a and Hydroxyurea with or without Low-Dose Cytosine Arabinoside.

Leukemia & lymphoma·2016
Same author

Multiple myeloma: the quality of care is linked to geographical and organisational determinants. A study in a French registry.

European journal of cancer care·2015
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
See all related articles

Interferon alpha (IFN alpha) shows promise in treating chronic myeloid leukemia and non-Hodgkin

Area of Science:

  • Hematology and Oncology
  • Immunology
  • Biochemistry

Context:

  • Interferon alpha (IFN alpha) has been utilized for decades in treating hematologic malignancies.
  • Its anti-viral, anti-proliferative, and immunomodulatory properties have been recognized.
  • Genetic engineering has expanded access to IFN alpha for therapeutic trials.

Purpose:

  • To evaluate the efficacy of IFN alpha in treating specific hemopathies.
  • To assess the role of IFN alpha compared to conventional treatments.
  • To explore future therapeutic strategies involving IFN alpha.

Summary:

  • Therapeutic trials over the past decade highlight IFN alpha's effectiveness in chronic myeloid leukemia (CML) achieving cytogenetic remission.
  • IFN alpha has also demonstrated utility in malignant non-Hodgkin's follicular lymphoma.

Related Experiment Videos

  • Its application in other hemopathies remains under investigation and is considered debatable.

    • Impact:

    • The future utility of IFN alpha in hemopathies hinges on combination therapies.
    • Potential combinations include IFN alpha with cytarabine or tyrosine kinase inhibitors for CML.
    • Associations with monoclonal antibodies, such as anti-CD20, are being explored for lymphomas.